ViiV Seeks Speedy EMA Review For Last-Resort HIV Drug
US Filing For Fostemsavir Expected This Year
Executive Summary
ViiV Healthcare has asked the European Medicines Agency to accelerate its review of fostemsavir when the company files for pan-EU market approval of the product.
You may also be interested in...
EU Accelerated Assessment Tracker
The European Medicines Agency this year is known to have granted ten requests for accelerated assessment of planned EU marketing authorization applications. Nine such requests are known to have been rejected. As 2019 draws to a close, the outcomes of five requests are still unknown.
December Sees Three Milestones For ViiV’s Pipeline
ViiV Healthcare’s R&D head Kimberly Smith tells Scrip December will see the advancement of three key HIV therapies.
EU Accelerated Assessment Tracker
Janssen’s two investigational Ebola vaccines are among four new products recently granted fast-track review by the European Medicines Agency. GlaxoSmithKline and Viiv Healthcare are not disclosing the outcomes of accelerated assessment requests they have made.